tbuckley/cabot-search huggingface dataset:
OP0057 Urinary and Serum KIM-1, MCP-1 and Type IV Collagen Levels in The Assessment of ANCA-Associated Nephritis Activity:
Authors: N. Bulanov, A. Serova, E. Kuznetsova, P. Novikov, S. Moiseev
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Kidney involvement is common in ANCA-associated vasculitis (AAV), but early detection of glomerulonephritis often presents a challenge. <h3>Objectives</h3> We evaluated diagnostic significance of urinary levels of kidney injury molecule-1 (uKIM-1), monocyte chemoattractant protein-1 (uMCP-1) and type IV collagen (uCollagenIV) and serum levels of MCP-1 (sMCP-1) and CollagenIV (sCollagenIV) and their relationship with nephritis activity and prognosis in AAV. <h3>Methods</h3> We enrolled 78 patients with AAV, diagnosed according to CHCC2012 definition (GPA=48, MPA=19, EGPA=11), 32 male, 46 female, aged 55 (45;61). To assess disease activity and kidney involvement we measured proteinuria, hematuria, serum creatinine (SCr), eGFR (CKD-EPI), BVAS and VDI. Urinary and serum concentrations of biomarkers were measured by ELISA. <h3>Results</h3> 28 patients had active renal AAV (35.9%, group 1), 26 had active nonrenal AAV (33.3%, group 2) and 24 were in long-term remission (30.8%, group 3). Median urinary levels of all biomarkers in active renal AAV were significantly higher than in groups 2 and 3 (Table), and did not depend on age and nosological form of AAV. Urinary excretion of all molecules was comparable in groups 2 and 3. There was a significant difference in sMCP-1 levels only between groups 1 and 3. sCollagenIV levels were similar in all groups. Significant positive correlations were found between urinary excretion of all biomarkers and features of nephritis activity: hematuria, proteinuria, renal component of BVAS (all p&lt;0.05). uCollagenIV level also had a significant positive correlation with SCr and a negative correlation with eGFR (all p&lt;0.05). sMCP-1 level showed no association with signs of nephritis activity, but had a positive correlation with CRP and total BVAS (p&lt;0.05). sCollagenIV level had no association with disease activity but had a correlation with SCr and eGFR (all p&lt;0.0001). ROC-analysis showed that uMCP-1≥159 pg/mL identified renal involvement with sensitivity 89%, specificity 67% (AUC 0.80). uKIM-1≥2283.3 pg/mL had similar sensitivity (92%) and lower specificity (58%), AUC 0.76. uCollagenIV≥3.09 mcg/L showed the worst sensitivity (57%), but the highest specificity (86%), AUC 0.76. <h3>Conclusions</h3> Urinary excretion of all biomarkers was significantly increased in active renal vasculitis. We suggest that uKIM-1 and uMCP-1 levels reflect local renal inflammation, while elevated uCollagenIV is likely to represent both glomerular basement membrane damage and activation of renal fibrogenesis. Limited specificity or sensitivity of individual urinary biomarkes may justify their combined use to identify active renal AAV. In contrast serum MCP-1 and CollagenIV only show a weak correlation with overall inflammatory activity and kidney dysfunction respectively, but have no association with nephritis activity. <h3>Disclosure of Interest</h3> None declared
PTU-158 The Influence of Social Class on Progression of Barrett’s Oesophagus to Oesophageal Adenocarcinoma: Abstract PTU-158 Table 1
Authors: S Bhattacharjee, CPJ Caygill, PAC Gatenby, A Watson
Journal: Gut (2016)

<h3>Introduction</h3> The incidence of oesophageal adenocarcinoma (OAC) has been rapidly increasing over the last three to four decades in many western nations, including the UK. Barrett’s oesophagus (BO) is the only known precursor condition for OAC. Surveillance of BO may be undertaken with the goal of detecting dysplasia and early neoplasia prior to the development of incurable cancer. The identification of subpopulations of subjects at highest risk of cancer development should allow more effective targeted surveillance. <h3>Methods</h3> Clinical records of 2896 patients from two centres in the UK, who have consented and registered with the UK Barrett’s Oesophagus Registry (UKBOR), were used for the purpose of this study. Data on patient’s occupation were obtained from hospital records, or from death certificates where available. The most widely used measure of social class in the UK is the ‘Registrar General’s Classification’ which assigns a social class category (I-V with subdivision of class III into III N [non-manual workers] and III M [manual workers] against individual occupation. Social class I are the professionals and higher managers, II and III are junior managers/supervisors, III and IV comprises of semiskilled and manual occupations and those in V are unskilled workers. A Chi-squared goodness of fit test was used to test for significance of the association of social class in both BO and OAC. <h3>Results</h3> In the BO group, 1824 people had usable information on occupation. <i>Table 1</i> shows the observed (O) cases of BO and OAC in each of the social classes and the number of expected (E) cases of OAC assuming an equal proportion of social class developed OAC (p-value – 0.003) The O/E results demonstrate an excess of patients progressing to OAC in social class III M, and a lower than expected number of cases in social classes I, III N and V. <h3>Conclusion</h3> Our study shows that more OAC is observed in BO patients in social class III M than expected whereas fewer are observed in social class I, IIIN and V than expected. <h3>References</h3> 1 Jansson C, Johansson AL, Nyren O, <i>et al</i>. Socioeconomicfactors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study. <i>Cancer Epidemiol Biomarkers Prev</i> 2005;<b>14</b>: 1754–1761. 2 Islami F, Kamnagar F, Nasrollahzadeh D, <i>et al</i>. Socio-economic status and oesophageal cancer: results from a population based case-control study in a high risk area. <i>Int J Epidemiol</i> 2009;<b>38</b>:978–988. <h3>Disclosure of Interest</h3> None Declared
Leading on Payment and Delivery Reform in Cardiology
Authors: Karen E. Joynt, Thomas M. Maddox
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
PCI with drug-eluting stents reduced revascularizations, but not mortality or MI, compared with bare-metal stents
Authors: Michael Hudson
Journal: Annals of Internal Medicine (2016)

ACP Journal Club15 November 2016PCI with drug-eluting stents reduced revascularizations, but not mortality or MI, compared with bare-metal stentsMichael Hudson, MD, MHS, FACCMichael Hudson, MD, MHS, FACCHenry Ford Hospital, Detroit, Michigan, USA (M.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-165-10-052 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationBønaa KH, Mannsverk J, Wiseth R, et al; NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242-52. https://pubmed.ncbi.nlm.nih.gov/27572953Clinical Impact RatingsCardiology: Reference1 Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873-91. [PMID: 22586281] Google Scholar Author, Article, and Disclosure InformationAffiliations: Henry Ford Hospital, Detroit, Michigan, USA (M.H.)This article was published at Annals.org on 1 November 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 November 2016Volume 165, Issue 10Page: JC52KeywordsCoronary arteriesDrugsLesionsMortalityMyocardial infarctionPercutaneous coronary interventionRevascularizationStable coronary artery diseaseStent implantation ePublished: 15 November 2016 Issue Published: 15 November 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
CTL Responses Against Tumor Associated Antigens Are Part of the Graft Versus Leukemia-Effect and Protect from Relapse after Allogeneic Hematopoetic Stem Cell Transplantation.
Authors: Markus Kapp, Stefan Stevanovic, Kerstin Fick, Juergen Loeffler, Sen Mui Tan, Andreas Opitz, Torsten Tonn, Hermann Einsele, Goetz Ulrich Grigoleit
Journal: Blood (2007)
Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease
Authors: Marian H. Harris, Traci M. Blonquist, Uma H. Athale, Luis A. Clavell, Peter D. Cole, Kara M. Kelly, Caroline Laverdiere, Jean-Marie Leclerc, Bruno Michon, Marshall A. Schorin, Jennifer J.G. Welch, Donna S. Neuberg, Stephen E. Sallan, Lewis B. Silverman
Journal: Blood (2015)
NF1 Microdeletions in Pediatric MLL-Rearranged AML and T-ALL: A Novel Mechanism for RAS Activation.
Authors: Brian V. Balgobind, Pieter Van Vlierberghe, Iris H. Hollink, Ans M.W. van den Ouweland, H. Berna Beverloo, Joan N.R. Terlouw-Kromosoeto, Elisabeth R. van Wering, Gertjan J.L. Kaspers, Dirk Reinhardt, Martin Horstmann, Karel Hahlen, Rob Pieters, Christian M. Zwaan, Jules P.P. Meijerink, Marry M. van den Heuvel-Eibrink
Journal: Blood (2007)
ΔNp73 /TAp73 Expression Ratio Is Associated with Ara-C-Induced Apoptosis Resistance in Acute Myeloid Leukemia.
Authors: Antonio Roberto L. Araújo, Rodrigo A. Panepucci, Rafael H. Jacomo, Guilherme A. Souza, Amélia G. Araújo, Ana Silvia G. Lima, Aglair B. Garcia, Roberto P. Falcao, Eduardo M. Rego
Journal: Blood (2007)
NIMG-06THE IMPACT OF HIGH GRADE GLIAL NEOPLASMS ON HUMAN CORTICAL ELECTROPHYSIOLOGY
Authors: S. Kathleen Bandt, Jarod Roland, Mrinal Pahwa, Carl Hacker, David Bundy, Jonathan Breshears, Mohit Sharma, Joshua Shimony, Eric Leuthardt
Journal: Neuro-Oncology (2015)
Hematopoietic Stem Cell Transplantation (HSCT) for Benign Indications Using Plasma Depleted Umbilical Cord Blood Units (UCB) That Were Not Depleted of Red Blood Cells.
Authors: Joseph Rosenthal, Tang-Her Jaing, Auayporn Nademanee, Chatchada Karanes, Michael Graham, Lee Lee Chan, Gretchen Eames, Ah Moy Tan, Poh-Lin Tan, Brian Wang, Peggy Tseng, Tiffany Chow, Tina Wu, Hai-Peng Lin, David Gjertson, Lawrence Petz, Patrick Tan, Robert Chow
Journal: Blood (2006)
Myeloma Cells Induce Osteoblast Suppression through Sclerostin Secretion
Authors: Silvia Colucci, Giacomina Brunetti, Angela Oranger, Giorgio Mori, Francesca Sardone, Vincenzo Liso, Paola Curci, Rosanna M Miccolis, Erminia Rinaldi, Giorgina Specchia, Giovanni Passeri, Alberta Zallone, Rita Rizzi, Maria Grano
Journal: Blood (2010)
Suppressed Neutrophil Development in Hematopoiesis of Induced Pluripotent Stem Cells Derived From a Severe Congenital Neutropenia Patient with ELA2 Mutation
Authors: Takafumi Hiramoto, Yasuhiro Ebihara, Yoko Mizoguchi, Kazuhiro Nakamura, Shinji Mochizuki, Shohei Yamamoto, Emiko Matsuzaka, Sachiyo Hanada, Ryoko Ohnishi, Kenzaburo Tani, Koji Eto, Hiromitsu Nakauchi, Masao Kobayashi, Kohichiro Tsuji
Journal: Blood (2011)
Does Thrombocytosis Alter the Prognosis of Myelodysplastic Syndromes (MDS) and MDS/Myeloproloferative Syndromes (MDS/MPD)? A Matched Case-Control Analysis of Outcomes.
Authors: Dhatri Kodali, Hector Mesa, Ajay Rawal, Qing Cao, Pankaj Gupta
Journal: Blood (2007)
Hierarchical Cluster Analysis of Immunophenotype in AML Patients with NPM1 Gene Mutation Reveals Two Distinct Groups with Different Prognosis.
Authors: Chien-Yuan Chen, Liang-In Lin, Wen-Chien Chou, Woei Tsay, Jih-Luh Tang, Sheng-Yi Huang, Hwei-Fang Tien
Journal: Blood (2008)
AB0014 Nanoparticles as MRI Contrast Agent for Early Diagnosis of RA: Effects of Amino-PVA-Coated SPIONS on CD4+ T Cell Activity
Authors: C. Strehl, L. Maurizi, S. Hermann, T. Häupl, H. Hofmann, F. Buttgereit, T. Gaber
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In medical applications nanotechnology provides new opportunities for diagnostic and therapeutic interventions in a variety of human diseases. Superparamagnetic iron oxide nanoparticles (SPION) are used as high-sensitive enhancer for magnetic resonance imaging, where they represent a promising tool for early diagnosis of destructive diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA). However, safety aspects still represent crucial problems for the further development of nanotechnology based products. Therefore, the focus of our work here was to identify more in detail putative unwanted effects of amino-polyvinyl alcohol-coated (a-PVA) SPION on human immune cell functions. <h3>Objectives</h3> Since we could demonstrate in former studies that professional phagocytes are activated by a-PVA-SPION, we here focused on the influence of these nanoparticles on human T helper cell activity. <h3>Methods</h3> PBMCs were isolated from blood samples obtained from healthy donors (HD, n≥9) or patients suffering from RA (n≥11). Primary human CD4 positive T cells were separated via MACS-Sort and incubated with the mitogen PHA-L (5μg/ml) and/or varying doses of a-PVA-SPION (1 μg/ml, 10 μg/ml, and 100 μg/ml) or left untreated for 20 h (analysis of caspase-3/7-activity, intracellular ATP content and CD25 expression) or 72 h (analysis of proliferation and CD25 expression). Cells were incubated under either normoxia (app. 18%O2) or hypoxia (1%O2) in order to mimic conditions found in the circulation and in the inflamed joint, respectively. <h3>Results</h3> We observed for PHA-L/a-PVA-SPION co-stimulated T cells from HD a decrease in cell count (all p&lt;0.05) whereas the caspase-3/7-activity is increased (all p&lt;0.05) in these samples, as expected. Although, we observed that T cells from RA patients are more susceptible to low-dose a-PVA-SPION-induced apoptosis than T cells from HD (p&lt;0.05), in both groups a-PVA-SPION do not activate CD4+ T cells <i>per se</i> and do not influence mitogen-mediated T cells activation with regard to CD25 expression and cell proliferation. Nevertheless, we were able to demonstrate that CD4+ T cells obtained from RA patients and healthy subjects differ in their response to mitogen stimulation and oxygen availability. <h3>Conclusions</h3> PVA-SPION at concentrations up to 100μg/ml do neither activate nor significantly influence mitogen-stimulated CD4+ T cells activation and have negligible influence on T cells apoptosis. <h3>Disclosure of Interest</h3> None declared
Diffuse-Large-B-Cell Lymphoma Patients with Secretory IgM Monoclonal Component Are A Very Poor Prognostic Subset.
Authors: M. Christina Cox, Arianna Di Napoli, Stefania Scarpino, Elena Cavalieri, Virginia Naso, Caterina Talerico, Gerardo Salerno, Caterina Tatarelli, Maria Antonietta Aloe Spiriti, Bruno Monarca, Sergio Amadori, Luigi Ruco
Journal: Blood (2012)
Relationship of Baseline Tumor Angiogenesis with Kinetics of Inflammatory Markers in DLBCL
Authors: Gaurav Prakash, Vaishali Aggarwal, Nidhi Jain, Amanjit Bal, Manupdesh Singh Sachdeva, Pankaj Malhotra, Alka Khadwal, Vikas Suri, Savita Kumari, Ashim Das, Subhash Varma
Journal: Blood (2015)
Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen
Authors: Kwee L Yong, Sarah Brown, Samantha Hinsley, Louise Flanagan, Neil Rabin, Karthik Ramasamy, Jamie Cavenagh, Roger G Owen, Martin F Kaiser, Eric Low, Catherine Williams
Journal: Blood (2015)
Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma
Authors: Daniel von Allmen, Andrew M. Davidoff, Wendy B. London, Collin Van Ryn, Daphne A. Haas-Kogan, Susan G. Kreissman, Geetika Khanna, Nancy Rosen, Julie R. Park, Michael P. La Quaglia
Journal: Journal of Clinical Oncology (2017)

Purpose This analysis of patients in the Children's Oncology Group A3973 study evaluated the impact of extent of primary tumor resection on local progression and survival and assessed concordance between clinical and central imaging review-based assessments of resection extent. Patients and Methods The analytic cohort (n = 220) included patients who had both central surgery review and resection of the primary tumor site. For this analysis, resection categories of < 90% and ≥ 90% were used, with data on resection extent derived from operating surgeons' assessments (all patients), as well as blinded central imaging review of computed tomography scans for a subset of 84 patients; assessment results were compared for concordance. Treatment outcomes included event-free survival (EFS), overall survival (OS), and cumulative incidence of local progression (CILP). Results Surgeon-assessed extent of resection was ≥ 90% in 154 (70%) patients and < 90% in 66 (30%). Five-year EFS, OS, and CILP (± SE) were 43.5% ± 3.7%, 54.9% ± 3.7%, and 11.9% ± 2.2%, respectively. EFS was higher with ≥ 90% resection (45.9% ± 4.3%) than with < 90% resection (37.9% ± 7.2%; P = .04). Lower CILP ( P = .01) was associated with ≥ 90% resection (8.5% ± 2.3%) compared with < 90% resection (19.8% ± 5.0%). On multivariable analysis, ≥ 90% resection was associated with longer EFS after adjustment for MYCN amplification or diploidy but had no significant effect on OS. Concordance between surgeons' assessments of resection extent and central image-guided review was low, with agreement of 63% (< 90% v ≥ 90%; simple κ = -0.0301). Conclusion Despite discordance between clinical assessment of resection extent and assessment via central imaging review, a surgeon-assessed resection extent ≥ 90% was associated with significantly better EFS and lower CILP. Improving OS, however, remains a challenge in this disease. These findings support continued attempts at ≥ 90% resection of the primary tumor in high-risk neuroblastoma.
In-Vitro Treatment of Chronic Lymphocytic Leukemia (CLL) Cells with Fludarabine, Etoposide and Alemtuzumab (Campath-1H) Reveals Different Rates and Mechanisms of Cell Death.
Authors: Dirk Winkler, Christof Schneider, Daniela Nitsch, Annett Habermann, Hartmut Doehner, Stephan Stilgenbauer
Journal: Blood (2005)
Modelling the long-term epidemiological and cost impact of a multicomponent lifestyle intervention and a sugar-sweetened beverage tax in the European Union: results from the EConDA project
Authors: Laura Pimpin, Carolina Perez-Ferrer, Andre Knuchel-Takano, Lise Retat, Abbygail Jaccard, Martin Brown, Laura Webber
Journal: The Lancet (2016)
[18 F]-Fludarabine Positron Emission Tomography in Chronic Lymphocytic Leukemia Patients: Results of a Phase I Study
Authors: Narinée Hovhannisyan, Sylvain P Chantepie, Meziane Ibazizene, Alain Manrique, Oumedaly Reman, Louisa Barre, Michel Leporrier
Journal: Blood (2015)
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients.
Authors: Antonio Palumbo, Sara Bringhen, Maria Teresa Petrucci, Antonietta Falcone, Anna Marina Liberati, Mariella Grasso, Francesco Pisani, Tommaso Caravita, Patrizia Pregno, Andrea Nozza, Paola Omedè, Patrizia Falco, Pellegrino Musto, Robin Foà, Mario Boccadoro
Journal: Blood (2006)
Macrophage Migration Inhibitory Factor Binds to CD74 on Gastric Epithelial Cells and Induces Pro-carcinogenic Events during Helicobacter pylori Infection
Authors: Marie Kveiborg, Archana Sanjay, Camilla Frohlich, Reidar Albrechtsen, Ulla M. Wewer
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

1673 

ADAM12 belongs to the family of ADAMs (A Disintegrin And Metalloproteases), which are multidomain proteins involved in a variety of biological processes (for review see Wewer et al., 2005 ). Human ADAM12 exists in two splice variants; a long form, ADAM12-L encompassing pro-, metalloprotease, disintegrin, cysteine-rich, EGF-like, transmembrane, and cytoplasmic domains, as well as a secreted form, ADAM12-S, lacking the transmembrane and cytoplasmic part. ADAM12 is an active metalloprotease and holds cell adhesion activities through complex interactions with the cell surface receptors, integrins and syndecans. Importantly, ADAM12 is upregulated in several human tumors and the level of ADAM12 in urine from breast cancer patients correlates with disease stage. Also, we recently reported that ADAM12 increases tumor aggressiveness in a mouse model of breast cancer, i.e. time to tumor burden was reduced, whereas tumor burden, metastasis, and histological grade were all increased ( Kveiborg et al., 2005 ). Moreover, tumors from mice overexpressing ADAM12 exhibit decreased tumor cell apoptosis, whereas stromal cell apoptosis was increased. Supporting these findings, in vitro studies showed that ADAM12 protects malignant cells from apoptosis while conferring increased apoptotic sensitivity in non-malignant cells. In many cancers abnormal events lead to elevated activity of the non-receptor tyrosine kinase c-Src (henceforth Src), thereby inducing transformation and metastasis. Interestingly, mouse ADAM12 has previously been shown to bind Src, become phosphorylated by the oncogenic form of Src, and co-localize with Src to actin structures in vitro. We here report the detailed mapping of the molecular interaction between the cytoplasmic tail of human ADAM12-L and Src. Extensive deletion and mutation analysis localized the interaction site to the SH3-binding site proximal to the transmembrane domain of ADAM12 and the SH3-domain of Src. Also, mutant forms of the Src SH3-domain that are not able to bind to proline-rich regions were used to validate the direct interaction. Based on these findings, we hypothesize that ADAM12 interacts with Src in tumor cells and thus might play mutual roles in cancer. Wewer, U.M., Engvall, E. and Albrechtsen, R. (2005) ADAM12: the long and the short of it. In: The ADAM Family of Proteases (Hooper, N.M. and Lendeckel, U., Eds.), Proteases in Biology and Disease, Vol. 4, Springer, The Netherlands. Kveiborg, M., Frohlich, C., Albrechtsen, R., et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res. 65:4754-61, 2005.